UK HTA Body To Conduct More Appraisals, And Faster, Through Proportionate Approach
Executive Summary
Faced with the rise in its workload, the UK’s health technology assessment body NICE is exploring ways of tailoring its approach to appraisals according to the type of product under consideration.
You may also be interested in...
UK’s NICE Slashes HTA Appraisal Time For Ngenla & Ofev Using New Approach
Ngenla and Ofev are the first two drugs to be evaluated using the health technology appraisal institute’s new proportionate approach – they were both appraised much faster than usual.
Companies Planning UK Investment Cuts Over Repayments Predicted for 2023
Many pharma firms are considering cutting their investment in clinical trials or reducing their supply to the UK market next year, a survey by industry group EMIG found.
Next UK Drug Pricing Scheme Needs ‘Single-Digit Fixed Rebates’
The pharmaceutical industry and the UK government are beginning a series of discussions on the shape of the future voluntary drug pricing and access scheme (VPAS), ahead of the formal negotiations that are scheduled to start in April.